Cardiff Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview

Cardiff Oncology

28/04/2025 12:23

Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to show a fall in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

The San Diego California-based  company is expected to report a 53.0% decrease in revenue to $96.43 thousand from $205 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.7% in the last three months. ​

Wall Street's median 12-month price target for Cardiff Oncology Inc is $14.00​, above​ its last closing price of $2.88. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.23
-0.24
-0.22
Beat
9
Sep. 30 2024
-0.27
-0.27
-0.25
Beat
7.4
Jun. 30 2024
-0.25
-0.26
Missed
-5.1​
Mar. 31 2024
-0.25
-0.25
-0.22
Beat
11.1
​​Dec. 31 2023
-0.27
-0.28
-0.21
Beat
24.3
Sep. 30 2023
-0.28
-0.28
-0.22
Beat
22.8​
Jun. 30 2023
-0.28
-0.26
-0.25
Beat
3.5
Mar. 31 2023
-0.22
-0.23
-0.25
Missed
-10.6

This summary was machine generated April 28 at 11:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)